Clinical Trials
96 trialsNCT06517758 2026-05-27
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06744920 2026-05-27
RELIEVE
Novartis
Phase 3 Recruiting
NCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07039916 2026-05-22
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT07246564 2026-05-22
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07595653 2026-05-19
POEMA
argenx
Recruiting
NCT07596901 2026-05-19
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07501702 2026-05-18
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06909253 2026-05-15
MG-ARCADIA
AstraZeneca
Recruiting
NCT06987539 2026-05-14
THYME
Amgen
Phase 2 Recruiting
NCT07247279 2026-05-13
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
AstraZeneca
Recruiting
NCT07337785 2026-05-12
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT07526493 2026-05-12
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
NCT06055959 2026-05-08
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-05-08
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06866652 2026-05-08
MyaRESP
Institut de Myologie, France
Recruiting
NCT07217587 2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06456580 2026-05-07
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07085676 2026-05-06
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Phase 1 Recruiting
NCT06447597 2026-04-30
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT06392386 2026-04-27
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT07284420 2026-04-23
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT07294170 2026-04-23
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
Recruiting
NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
NCT06312644 2026-04-16
Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy
Alexion Pharmaceuticals, Inc.
Recruiting
NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT06754020 2026-04-13
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
National Taipei University of Nursing and Health Sciences
Phase NA Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06704269 2026-04-06
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting
NCT06491238 2026-03-23
MG-Ex
HealthPartners Institute
Phase NA Recruiting
NCT07413835 2026-03-18
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
The Affiliated Hospital of Xuzhou Medical University
Phase NA Recruiting
NCT07478172 2026-03-17
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
Phase NA Recruiting
NCT05265273 2026-03-13
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3 Recruiting
NCT07470151 2026-03-13
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06626919 2026-02-25
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Phase 1 Recruiting
NCT07215949 2026-02-23
Zilucoplan for Severe gMG Exacerbations
Ohio State University
Phase 3 Recruiting
NCT04202341 2026-02-18
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Alexion Pharmaceuticals, Inc.
Recruiting
NCT04833894 2026-02-18
ADAPT Jr
argenx
Phase 2/3 Recruiting
NCT06298565 2026-02-17
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
argenx
Recruiting
NCT06299748 2026-02-17
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
argenx
Recruiting
NCT07411963 2026-02-17
EARLY-MG
Centre Hospitalier Universitaire de Nice
Recruiting
NCT07250750 2026-02-11
Synergy-MG
ImmunAbs Inc.
Phase 1/2 Recruiting
NCT06220201 2026-02-10
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT06967480 2026-02-05
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Recruiting